|
Adam Stops, PhD, says the key to the success of any drug delivery device are factors such as proven technology, low development costs, fast time-to-market, and a strong intellectual property (IP) position for the pharma company, and against this background, platform drug delivery devices have become more important than ever.
|
|
|
Eleanor Row, PhD, explores the current challenges drug developers face in transitioning their candidate molecules to first-in-human (FIH) clinical trials, including what the different drug development functions should be considering at this stage, and how an integrated approach can help to accelerate your molecule’s pathway to trial and beyond.
|
|
|
Ross Errington explores the latest developments in the pMDI segment and explains the steps pharmaceutical companies need to take to ensure their pMDI drug products are ready to thrive in a very different market environment.
|
|
|
Nicolas Buchmann, PhD, explores the opportunities and challenges of developing biologic formulations for delivery via SMIs and discusses the importance and impact of partnerships between inhalation device development experts when it comes to facilitating the innovation needed to expand the suitability of SMIs to a wider range of biopharma formulations.
|
|
|
|
|

Douglas CDMO, based in New Zealand, has a history dating back to 1967. We offer end-to-end integrated drug development services, specializing in high-potency small molecule softgels, liquids, semi-solids, new chemical entities (NCEs), and branded generics. Our capabilities extend to manufacturing prescription drugs across key therapeutic areas, including oncology, dermatology, the central nervous system, and immunity. Working with clients across the globe, we pride ourselves on delivering superior quality and excellent service, ensuring our partners achieve successful, timely outcomes. Our strategic location in Auckland, New Zealand offers our global customers with tax incentives and the ability to start first in human trials quicker than many other jurisdictions due to a streamlined regulatory process. Click here for more.
|